In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...
Read More
In a nutshell This study compared the effectiveness and safety of ibrutinib (Imbruvica) versus temsirolimus (Torisel) in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib significantly improved survival outcomes compared to temsirolimus for these patients. Some background...
Read More
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read More
In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...
Read More
In a nutshell This study determined the outcomes of early-stage classical Hodgkin’s lymphoma (HL) patients who received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and radiotherapy (RT) only. The study concluded that patients who showed a good partial response (tumor shrinkage) to ABVD chemotherapy were successfully...
Read More
In a nutshell This study determined the effectiveness and safety of brentuximab vedotin (Adcetris) administered with AVD (doxorubicin, vinblastine, dacarbazine) chemotherapy for stage 3 or 4 classical HL (Hodgkin’s lymphoma). The study concluded that brentuximab vedotin with AVD was more effective than ABVD (AVD plus bleomycin). Some...
Read More
In a nutshell This study determined whether certain risk factors predicted outcomes in primary refractory Hodgkin lymphoma. The authors concluded that risk factors such as stage IV disease and cancer activity seen on imaging predicted worse overall outcomes. Some background Refractory disease Hodgkin lymphoma patients are those who are...
Read MoreIn a nutshell This trial examined the quality-of-life (QOL) impact of an antibody therapy among patients who had already undergone standard treatment for relapsed- or refractory disease. The authors concluded that the treatment modestly decreased QOL during certain time periods only. Some background Hodgkin Lymphoma is generally highly...
Read More
In a nutshell This trial examined the need for radiotherapy among early-stage Hodgkin lymphoma patients who responded well to chemotherapy. The authors concluded that in these patients, progression-free survival rates were high overall, but were slightly higher with additional radiation. Some background Hodgkin lymphoma is a cancer...
Read More
In a nutshell This study assessed whether patients with relapsed- or refractory Hodgkin Lymphoma should be treated with radiation therapy. The authors concluded that radiation therapy was safe and prevented the return of the disease in certain patients. Some background Hodgkin lymphoma is a cancer of the lymph system. It is a...
Read MoreIn a nutshell This scientific article tried to prove that acquired resistance to the chemotherapeutic agent Docetaxel (Taxotere) can be eliminated by specifically targeting the mechanisms of resistance with additional drugs. The main finding was that a new cocktail of chemotherapeutic drugs can inhibit resistance to Docetaxel in studies performed on...
Read More
